Despite this remarkable progress in cancer immunotherapies, multiple lines of evidence indicate that antibody therapies targeting immune checkpoint markers, such as CTLA4, PD-1, or PD-L1, often lead to severe adverse drug reactions resulting from an elevated immune response (10). This evidence concerns the gene CTLA4 and cancer.